GlycoMimetics to Present at Upcoming Healthcare Investor Conferences

ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at two healthcare investor conferences next week, as follows:

STIFEL 2016 HEALTHCARE CONFERENCEWHEN: NOVEMBER 15, 2016 AT 4:30 PM ETWHERE: NEW YORK, NY, USA

JEFFERIES 2016 LONDON HEALTHCARE CONFERENCEWHEN: NOVEMBER 17, 2016 AT 1:20 PM GMTWHERE: LONDON, UK

To access the live webcast and subsequent archived recordings for the presentation, please visit the GlycoMimetics website at www.glycomimetics.com.

About GlycoMimetics, Inc.

GlycoMimetics is a clinical-stage biotechnology company focused on cancer and sickle cell disease. GlycoMimetics’ most advanced drug candidate, rivipansel, a pan-selectin antagonist, is being developed for the treatment of vaso-occlusive crisis in sickle cell disease and is being evaluated in a Phase 3 clinical trial being conducted by its strategic collaborator, Pfizer. GlycoMimetics’ wholly-owned drug candidate, GMI-1271, an E-selectin antagonist, is being evaluated in an ongoing Phase 1/2 clinical trial as a potential treatment for AML and in a Phase 1 clinical trial in multiple myeloma. GlycoMimetics has also recently initiated a clinical trial with a third drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20161110005722/en/

GlycoMimetics, Inc.
Investor Contact:
Shari Annes, 650-888-0902
[email protected]
or
Media Contact:
Jamie Lacey-Moreira, 410-299-3310
[email protected]

Source: GlycoMimetics, Inc.

You May Also Be Interested In

• Jefferies Starts Latigo Biotherapeutics (LTGO) at Buy
• ReconAfrica Announces C$15 Million Bought-Deal Public Offering to Conduct Horizontal Sidetrack and Production Testing Program at the Kavango West 1X of the Huttenberg Formation
• Clean electricity supplied 40% of new energy demand in 2025. Faster deployment and sectoral breakthroughs can cut emissions permanently, says annual Energy Transition Monitor